Previous 10 | Next 10 |
Rocket Pharmaceuticals press release (NASDAQ:RCKT): Q4 GAAP EPS of -$0.69 beats by $0.04. Cash, cash equivalents and investments as of December 31, 2021, were $388.7 million. For further details see: Rocket Pharmaceuticals GAAP EPS of -$0.69 beats by $0.04
— Positive Phase 1 data from Danon Disease gene therapy trial demonstrated sustained benefit across clinical, functional and biomarker endpoints in all four adult patients with long-term follow up; pediatric cohort data expected Q3 2022 — — Reported engraf...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11...
— Top-line data from pivotal LAD-I and Fanconi Anemia trials anticipated in Q2 and Q3, respectively — — Danon Disease pediatric patient cohort data expected Q3 — — In-house AAV GMP manufacturing initiation anticipated in Q2 — ...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at...
—Evidence of engraftment observed in six patients with at least 12-months of follow-up after treatment with RP-L102 in Fanconi Anemia with MMC resistance between 16% and 63% at a minimum of one timepoint— —All eight initial patients with follow-up from 3 t...
—Data updates to be presented from ongoing Phase 2 registrational trials in LAD-I and FA and Phase 1 trial in PKD — Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies f...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Evercore I...
Rocket Pharmaceuticals (RCKT -17.5%) has recorded the biggest intra-day loss since March 2020 after the company disclosed its plans not to pursue a high-dose cohort in Phase 1 clinical trial for RP-A501 in adult and adolescent patients with Danon Disease. The study was designed to evalua...
Gainers: Creative Realities (NASDAQ:CREX) +128%. Casper Sleep (NYSE:CSPR) +86%. Siyata Mobile (NASDAQ:SYTA) +33%. Patriot National Bancorp (NASDAQ:PNBK) +35%. SilverSun Technologies (NASDAQ:SSNT) +26%. The Vita CoCo (NASDAQ:COCO) +24%. Trio-Tech (NYSE:TRT) +24%. Gores Guggenheim (NASDAQ:GGPI)...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...